oxonic acid has been researched along with Leukocytopenia in 61 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 9.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Combination chemotherapy consisting of carboplatin plus S-1 and concurrent TRT had a promising efficacy in elderly patients with locally advanced NSCLC; however, radiation pneumonitis was frequently observed." | 5.30 | Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study. ( Akimoto, T; Goto, K; Hida, T; Hosomi, Y; Nihei, K; Niho, S; Ohe, Y; Okamoto, H; Tanaka, H; Umemura, S, 2019) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 5.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| "Nab-paclitaxel plus S1 was more efficient in terms of ORR and DCR than S1 monotherapy in elderly pancreatic ductal adenocarcinoma patients while the side effect was controllable with a higher probability of leukopenia." | 5.12 | Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. ( Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021) |
| " Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)." | 5.10 | [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| " After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| " The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "Irinotecan (80 mg/m2) was infused on Days 1, 8, 22, and 29." | 2.76 | A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| " Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity." | 2.76 | [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011) |
| " Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle." | 2.75 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010) |
| "Paclitaxel was administered by intravenous drip infusion at a starting dose (level 1) of 50 mg/m2 on days 1, 8, and 15." | 2.72 | [A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer]. ( Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T, 2006) |
| "He died of brain metastases." | 2.72 | [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. ( Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H, 2006) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| " We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis." | 2.43 | [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
| "Grade 3 leukocytopenia was observed in 1 patient (8." | 1.35 | Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. ( Dono, K; Kobayashi, S; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Takeda, Y; Umeshita, K; Wada, H, 2008) |
| "We report a case of recurrent gastric cancer with peritoneal dissemination and paraaortic lymph node metastases, successfully treated with weekly administration of paclitaxel." | 1.34 | [A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel]. ( Hirata, K; Ito, T; Sato, T; Takashima, T, 2007) |
| "As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis." | 1.33 | [Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--]. ( Ito, K, 2006) |
| " The adverse effects observed were grade 3 leukopenia in 2 patients (11." | 1.33 | [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]. ( Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006) |
| "The methods consisted of analysis of background factors, assessment of the administration and dosage of TS-1, and associations with adverse reactions." | 1.32 | [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients]. ( Hara, A; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T, 2004) |
| "We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1." | 1.32 | [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. ( Mishima, K; Nakamura, H; Obara, S; Yamamoto, K; Yoshimura, Y, 2004) |
| "Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence." | 1.32 | [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital]. ( Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003) |
| "Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP)." | 1.31 | [TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy]. ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Nakaguchi, K; Nakamura, M; Sue, F; Tanaka, J; Yokouchi, H; Yoshihara, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.28) | 18.2507 |
| 2000's | 37 (60.66) | 29.6817 |
| 2010's | 20 (32.79) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 1 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Chen, Y | 1 |
| Gu, J | 1 |
| Yin, M | 1 |
| Wang, C | 1 |
| Chen, D | 1 |
| Yang, L | 1 |
| Chen, X | 1 |
| Lin, Z | 1 |
| Du, J | 1 |
| Cui, S | 1 |
| Ma, C | 1 |
| Luo, H | 1 |
| Wang, F | 1 |
| Fan, QX | 1 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Niho, S | 1 |
| Hosomi, Y | 1 |
| Okamoto, H | 1 |
| Nihei, K | 1 |
| Tanaka, H | 2 |
| Hida, T | 1 |
| Umemura, S | 1 |
| Goto, K | 1 |
| Akimoto, T | 1 |
| Ohe, Y | 1 |
| Huang, D | 1 |
| Ba, Y | 2 |
| Xiong, J | 1 |
| Xu, N | 2 |
| Yan, Z | 2 |
| Zhuang, Z | 1 |
| Yu, Z | 3 |
| Wan, H | 1 |
| Zhang, Y | 2 |
| Deng, T | 2 |
| Zheng, R | 1 |
| Guo, Z | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 2 |
| Meng, J | 1 |
| Kaira, K | 2 |
| Tomizawa, Y | 1 |
| Yoshino, R | 1 |
| Yoshii, A | 1 |
| Matsuura, M | 1 |
| Iwasaki, Y | 2 |
| Koga, Y | 1 |
| Ono, A | 1 |
| Nishioka, M | 1 |
| Kamide, Y | 1 |
| Hisada, T | 2 |
| Ishizuka, T | 2 |
| Shirai, K | 1 |
| Ebara, T | 1 |
| Saitoh, J | 1 |
| Nakano, T | 1 |
| Sunaga, N | 2 |
| Dong, L | 1 |
| Li, J | 1 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Nakamura, T | 3 |
| Yamashita, K | 3 |
| Sato, T | 5 |
| Ema, A | 1 |
| Naito, M | 2 |
| Watanabe, M | 4 |
| Arima, S | 1 |
| Shimizu, K | 2 |
| Okamoto, T | 2 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 2 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Sugiyama, M | 1 |
| Furuse, J | 2 |
| Yanagitani, N | 1 |
| Aoki, H | 1 |
| Kawata, T | 1 |
| Utsugi, M | 1 |
| Shimizu, Y | 1 |
| Mori, M | 1 |
| Park, I | 1 |
| Lee, JL | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Sym, SJ | 1 |
| Lee, SS | 1 |
| Jang, G | 1 |
| Yoo, C | 1 |
| Bae, KS | 1 |
| Kang, YK | 1 |
| Oh, DY | 1 |
| Cha, Y | 1 |
| Choi, IS | 1 |
| Yoon, SY | 1 |
| Choi, IK | 1 |
| Kim, JH | 1 |
| Oh, SC | 1 |
| Kim, CD | 1 |
| Kim, JS | 1 |
| Bang, YJ | 1 |
| Kim, YH | 1 |
| Sasaki, T | 4 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Ito, Y | 1 |
| Kogure, H | 1 |
| Togawa, O | 1 |
| Toda, N | 1 |
| Yasuda, I | 1 |
| Hasebe, O | 1 |
| Maetani, I | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Tsujino, T | 1 |
| Tada, M | 1 |
| Omata, M | 1 |
| Koizumi, W | 3 |
| Akiya, T | 1 |
| Sato, A | 1 |
| Sakuyama, T | 1 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Hamada, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Shimada, K | 1 |
| Mine, T | 1 |
| Yamaguchi, K | 1 |
| Kurihara, M | 1 |
| Yokoyama, T | 1 |
| Tokuhara, H | 1 |
| Egawa, T | 1 |
| Hashimoto, O | 1 |
| Seki, H | 1 |
| Koyanagi, K | 1 |
| Bessho, T | 1 |
| Yanagihara, K | 1 |
| Yoshimura, K | 1 |
| Niimi, M | 1 |
| Yasuda, H | 1 |
| Nishimura, T | 1 |
| Ishiguro, H | 1 |
| Matsumoto, S | 1 |
| Kitano, T | 1 |
| Kanai, M | 1 |
| Misawa, A | 1 |
| Tada, H | 1 |
| Teramukai, S | 1 |
| Mio, T | 1 |
| Fukushima, M | 1 |
| Ozawa, H | 1 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Ihara, A | 1 |
| Hayakawa, K | 1 |
| Okayasu, I | 1 |
| Tsushima, T | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Machida, N | 1 |
| Yamazaki, K | 2 |
| Yasui, H | 1 |
| Taku, K | 1 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Takagawa, R | 1 |
| Kunisaki, C | 2 |
| Makino, H | 1 |
| Nagano, Y | 1 |
| Fujii, S | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Komatsu, Y | 2 |
| Yuki, S | 2 |
| Sogabe, S | 1 |
| Fukushima, H | 1 |
| Iwanaga, I | 1 |
| Kudo, M | 2 |
| Tateyama, M | 2 |
| Meguro, T | 1 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Sakata, Y | 2 |
| Asaka, M | 2 |
| Ueno, H | 1 |
| Okusaka, T | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Ohkawa, S | 1 |
| Yokosuka, O | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Nakamori, S | 1 |
| Nakayama, N | 1 |
| Tanabe, S | 1 |
| Higuchi, K | 1 |
| Nishimura, K | 1 |
| Takagi, S | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Ishido, K | 1 |
| Nakatani, K | 1 |
| Naruke, A | 1 |
| Katada, C | 1 |
| Zhu, QC | 1 |
| Jin, ZM | 1 |
| Huang, DZ | 1 |
| Xiong, JP | 1 |
| Zhuang, ZX | 1 |
| Wan, HP | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 1 |
| Meng, JC | 1 |
| Nakamura, M | 2 |
| Maruyama, K | 1 |
| Furukawa, J | 1 |
| Maruyama, N | 1 |
| Tanaka, J | 1 |
| Katsumoto, Y | 1 |
| Yokouchi, H | 1 |
| Nakaguchi, K | 1 |
| Sue, F | 1 |
| Yoshihara, W | 1 |
| Nishino, H | 1 |
| Shinozaki, T | 1 |
| Ishikawa, K | 1 |
| Ichimura, K | 1 |
| Abe, S | 1 |
| Kojima, M | 1 |
| Tamura, H | 1 |
| Kurihara, H | 1 |
| Kitago, M | 1 |
| Ogihara, T | 1 |
| Arai, K | 1 |
| Kimura, Y | 2 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Honma, S | 1 |
| Takahashi, T | 1 |
| Yamamura, Y | 1 |
| Kodera, Y | 1 |
| Tanemura, H | 1 |
| Oshita, H | 1 |
| Miyashita, K | 1 |
| Fujimura, T | 1 |
| Aotake, T | 1 |
| Yamamoto, H | 1 |
| Tanaka, F | 1 |
| Fujii, H | 1 |
| Hirose, Y | 1 |
| Matsushita, T | 1 |
| Morita, S | 1 |
| Ohashi, Y | 1 |
| Hirakawa, K | 1 |
| Nakata, B | 1 |
| Saji, S | 1 |
| Sakamoto, J | 1 |
| Saeki, T | 1 |
| Takashima, S | 2 |
| Sano, M | 2 |
| Horikoshi, N | 2 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 2 |
| Kimura, M | 2 |
| Taguchi, T | 3 |
| Hara, A | 1 |
| Tokuhara, T | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 1 |
| Iwamoto, S | 1 |
| Satake, K | 1 |
| Makari, Y | 1 |
| Fujiwara, Y | 2 |
| Yasuda, T | 2 |
| Takiguchi, S | 2 |
| Yano, M | 1 |
| Monden, M | 3 |
| Yamamoto, K | 1 |
| Obara, S | 1 |
| Mishima, K | 1 |
| Nakamura, H | 1 |
| Yoshimura, Y | 1 |
| Nukaya, H | 1 |
| Hirashima, N | 1 |
| Tanaka, Y | 1 |
| Endo, M | 1 |
| Matsunaga, S | 1 |
| Hasegawa, I | 1 |
| Kato, A | 1 |
| Sakakibara, K | 1 |
| Sakamoto, T | 1 |
| Kondo, H | 1 |
| Fujita, J | 1 |
| Kan, K | 1 |
| Tsukahara, K | 1 |
| Miyata, H | 1 |
| Doki, Y | 1 |
| Ito, K | 1 |
| Takahashi, I | 2 |
| Emi, Y | 1 |
| Kakeji, Y | 2 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Oki, E | 2 |
| Baba, H | 1 |
| Maehara, Y | 2 |
| Wataya, H | 1 |
| Asou, H | 1 |
| Maruyama, R | 1 |
| Suemitsu, R | 1 |
| Ichinose, Y | 1 |
| Itoi, A | 1 |
| Takashima, M | 1 |
| Ishimasa, H | 1 |
| Murata, H | 1 |
| Tomoda, K | 1 |
| Shitara, K | 1 |
| Kudou, T | 1 |
| Munakata, M | 1 |
| Ohtsu, A | 1 |
| Yoshida, K | 1 |
| Wada, Y | 1 |
| Tanabe, K | 1 |
| Ukon, K | 1 |
| Hihara, J | 1 |
| Egashira, A | 1 |
| Morita, M | 1 |
| Hokita, S | 1 |
| Aikou, T | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Nakajo, A | 1 |
| Uenosono, Y | 1 |
| Hamanoue, M | 1 |
| Aridome, K | 1 |
| Natsugoe, S | 1 |
| Eguchi, T | 1 |
| Shirao, K | 1 |
| Goto, A | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 1 |
| Kamiyama, G | 1 |
| Narita, K | 1 |
| Suzuki, N | 1 |
| Oonaka, T | 1 |
| Kusano, M | 1 |
| Tsuji, H | 1 |
| Nagata, M | 1 |
| Inoue, T | 1 |
| Minami, T | 1 |
| Iwai, H | 1 |
| Ohnishi, S | 1 |
| Yukawa, H | 1 |
| Ogura, M | 1 |
| Yamashita, T | 1 |
| Nagata, K | 1 |
| Tsukuda, M | 2 |
| Ishitoya, J | 1 |
| Mikami, Y | 1 |
| Matsuda, H | 1 |
| Katori, H | 1 |
| Horiuchi, C | 1 |
| Yoshida, T | 1 |
| Toth, G | 1 |
| Tahara, M | 1 |
| Nakazawa, M | 1 |
| Hatori, S | 1 |
| Ono, H | 1 |
| Otsuka, Y | 1 |
| Yamada, R | 1 |
| Ohshima, T | 1 |
| Rino, Y | 1 |
| Imada, T | 1 |
| Matsumoto, H | 1 |
| Hirai, T | 1 |
| Hirabayashi, Y | 1 |
| Murakami, H | 1 |
| Higashida, M | 1 |
| Kawabe, Y | 1 |
| Urakami, A | 1 |
| Hiratsuka, J | 1 |
| Imajyo, Y | 1 |
| Tsunoda, T | 1 |
| Maruoka, Y | 1 |
| Ando, T | 1 |
| Ogiuchi, Y | 1 |
| Ogiuchi, H | 1 |
| Takashima, T | 1 |
| Ito, T | 1 |
| Hirata, K | 1 |
| Nagano, H | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Takeda, Y | 1 |
| Kobayashi, S | 1 |
| Wada, H | 1 |
| Noda, T | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Toge, T | 1 |
| Aoyama, H | 1 |
| Ota, J | 1 |
| Noguchi, S | 1 |
| Inuyama, Y | 1 |
| Kida, A | 1 |
| Kohno, N | 1 |
| Satake, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for oxonic acid and Leukocytopenia
| Article | Year |
|---|---|
Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
[An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Inj | 2005 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Topics: Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Ad | 2006 |
39 trials available for oxonic acid and Leukocytopenia
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2019 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dr | 2013 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat | 2010 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2010 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi | 2012 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo | 2011 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini | 2003 |
[A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administratio | 2004 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dr | 2006 |
[Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia, Megaloblastic; Antimetabolites, Antineoplasti | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal | 2006 |
[Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deglutit | 2006 |
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati | 1998 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
15 other studies available for oxonic acid and Leukocytopenia
| Article | Year |
|---|---|
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dise | 2009 |
Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2011 |
[TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedul | 2002 |
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co | 2002 |
[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration | 2003 |
[A case of postoperative chestwall recurrence of gastric cancer responding to a combination of radiation, hyperthermia and oral administration of TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Sch | 2004 |
[Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedul | 2004 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu | 2004 |
[An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administrat | 2004 |
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Mon | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administrat | 2006 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combin | 2007 |
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2008 |